

The listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Cancel claims 1 to 44, without prejudice.


45. (original) A method for treating pain comprising the step of administering to a mammal a therapeutically effective amount of an agent to alleviate pain, the agent comprises
a therapeutic component, and
a targeting component,
wherein the targeting component selectively binds at the alpha-2B or alpha-2B/alpha-2C adrenergic receptor subtype(s) as compared to the alpha-2A adrenergic receptor subtype.

46. (original) A method according to claim 45 wherein the pain alleviated is chronic pain.

47. (original) A method for treating pain according to claim 45 which further comprises a translocation component.

48. (original) A method according to claim 47 wherein
the therapeutic component comprises a light chain of botulium toxin type A;
the translocation component comprises a fragment of the heavy chain of botulinum toxin type A which is able to facilitate the transfer of at least the light chain into the cytoplasm of the target cell; and

targeting component is represented by the general formula:



wherein X is selected from the group consisting of $R_4-C=C-R_5$ and R_4-C ;

a six membered carbon ring structure is formed when X is $R_4-C=C-R_5$;

a five membered carbon ring is formed when X is R_4-C ;

R_1 , R_2 , R_3 , R_4 and R_5 are each independently selected from the group consisting of F, Cl, Br, I, OR_6 and H, wherein R_6 is H or an alkyl, including a methyl, an ethyl or a propyl.

49. (original) A method according to claim 47 wherein the therapeutic component and the translocation component are part of a botulium toxin.

50. (original) A method according to claim 49 wherein the botulinum toxin is type A.

51. (original) A method according to claim 50 wherein the agent comprises about 1 U to about 500 U of the botulinum toxin.

52. (original) A method according to claim 50 wherein the agent comprises about 10 U to about 300 U of the botulinum toxin.

53. (original) A method according to claim 50 wherein the pain alleviation persists from about 2 to about 27 months.

54. (original) A method according to claim 45 wherein the agent is administered intrathecally.

55. (original) A method according to claim 45 wherein the agent is administered intrathecally to a cranial region of the central nervous system.

56. (original) A method according to claim 45 wherein the agent is administered intrathecally to a cervical region of the central nervous system.

57. (original) A method according to claim 45 wherein the agent is administered intrathecally to a thoracic region of the central nervous system.

58. (original) A method according to claim 45 wherein the agent is administered intrathecally to a lumbar region of the central nervous system.

59. (original) A method according to claim 45 wherein the agent is administered intrathecally to a sacral region of the central nervous system.

60. (original) A method according to claim 45 wherein the agent is administered intramuscularly.

61. (original) A method according to claim 45 wherein the agent is administered subcutaneously.

62. (original) A method according to claim 45 wherein the pain is chronic pain.

63. (original) A method according to claim 45 wherein the pain is visceral pain.

64. (original) A method according to claim 45 wherein the pain is neuropathic pain.

65. (original) A method according to claim 45 wherein the pain is referred pain.

66. (original) A method according to claim 45 wherein the pain is a allodynia type pain.

67. (original) A method according to claim 63 wherein the allodynia type pain is alleviated without substantially affecting acute pain sensation or tactile sensation.